6533b86efe1ef96bd12cb473
RESEARCH PRODUCT
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
Filippo SprianoCorentin MoulinIrem DenizVirginia SpanòAna R Díaz MarreroAyşegül ErdoğanAna RotterMohamed MehiriMercedes CuetoPaola BarrajaGiuseppe PeraleFrancesco BertoniMarilia BarrecaElisabeth Taffin-de-givenchySusana P. GaudêncioAlessandra MontalbanoOlivier P. ThomasLada Lukić-bilelasubject
Eribulin MesylateAquatic OrganismsEnfortumab vedotinLurbinectedinPharmaceutical ScienceAntineoplastic AgentsMarine drugsComputational biologyReviewBiology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSDG 3 - Good Health and Well-beingNeoplasmsmedicineAnimalsHumansSDG 14 - Life Below WaterBrentuximab vedotinlcsh:QH301-705.5Pharmacology Toxicology and Pharmaceutics (miscellaneous)030304 developmental biologyFludarabine Phosphate0303 health sciencesBiological ProductsDrug discoveryDrug discoveryClinical pipelinePolatuzumab vedotinAnticancerlcsh:Biology (General)chemistry030220 oncology & carcinogenesisMarine natural productsMarine ToxinsPlitidepsinWater Microbiologymedicine.drugdescription
The marine environment is a rich source of biologically active molecules for the treatment of human diseases, especially cancer. The adaptation to unique environmental conditions led marine organisms to evolve di erent pathways than their terrestrial counterparts, thus producing unique chemicals with a broad diversity and complexity. So far, more than 36,000 compounds have been isolated from marine micro- and macro-organisms including but not limited to fungi, bacteria, microalgae, macroalgae, sponges, corals, mollusks and tunicates, with hundreds of new marine natural products (MNPs) being discovered every year.Marine-based pharmaceuticals have started to impactmodern pharmacology and different anti-cancer drugs derived frommarine compounds have been approved for clinical use, such as: cytarabine, vidarabine, nelarabine (prodrug of ara-G), fludarabine phosphate (pro-drug of ara-A), trabectedin, eribulin mesylate, brentuximab vedotin, polatuzumab vedotin, enfortumab vedotin, belantamab mafodotin, plitidepsin, and lurbinectedin. This review focuses on the bioactive molecules derived from the marine environment with anticancer activity, discussing their families, origin, structural features and therapeutic use.
year | journal | country | edition | language |
---|---|---|---|---|
2020-12-04 |